- Investing Ideas
- /
- Global Pharmaceuticals & Biotech Strong Balance Sheet with Growth Potential
Global Pharmaceuticals & Biotech Strong Balance Sheet with Growth Potential
Results
14
Stocks with plenty of capacity to fund future growth
14 companies
Neurocrine Biosciences
Market Cap: US$14.1b
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally.
NBIX
US$142.00
7D
-2.2%
1Y
23.4%
Exelixis
Market Cap: US$10.4b
An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
EXEL
US$39.04
7D
-2.6%
1Y
50.4%
Corcept Therapeutics
Market Cap: US$8.7b
Engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.
CORT
US$83.87
7D
4.2%
1Y
90.9%
Krystal Biotech
Market Cap: US$4.7b
A commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States.
KRYS
US$167.82
7D
2.6%
1Y
-5.3%
Protagonist Therapeutics
Market Cap: US$4.0b
A biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases.
PTGX
US$67.42
7D
8.4%
1Y
51.3%
ADMA Biologics
Market Cap: US$3.7b
A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
ADMA
US$15.61
7D
-1.9%
1Y
-19.5%
ACADIA Pharmaceuticals
Market Cap: US$3.6b
A biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States.
ACAD
US$21.05
7D
-13.8%
1Y
34.2%
Kiniksa Pharmaceuticals International
Market Cap: US$2.6b
A biopharmaceutical company, developing and commercializing novel therapies for diseases with unmet need and focuses on cardiovascular indications worldwide.
KNSA
US$36.49
7D
3.0%
1Y
46.0%
Harmony Biosciences Holdings
Market Cap: US$1.6b
A commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States.
HRMY
US$27.51
7D
-15.5%
1Y
-29.7%
Vericel
Market Cap: US$1.5b
A commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America.
VCEL
US$30.23
7D
-4.6%
1Y
-30.0%
MiMedx Group
Market Cap: US$1.0b
Develops and distributes placental tissue allografts for various sectors of healthcare.
MDXG
US$6.94
7D
-1.1%
1Y
19.0%
CorMedix
Market Cap: US$868.0m
A biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.
CRMD
US$11.30
7D
0.9%
1Y
40.4%
Niagen Bioscience
Market Cap: US$752.0m
Operates as a bioscience company engages in developing healthy aging products.
NAGE
US$9.76
7D
-1.0%
1Y
156.8%
SIGA Technologies
Market Cap: US$628.7m
A commercial-stage pharmaceutical company, focuses on the health security market in the United States.
SIGA
US$9.16
7D
4.3%
1Y
31.6%